{"filing":{"accession_number":"0001213900-26-086123","cik":"0001985062","ticker":"PBMWW","company_name":"PSYENCE BIOMEDICAL LTD.","form":"6-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"ea0300579-6k_psyence.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1985062/000121390026086123/ea0300579-6k_psyence.htm"},"events":[{"id":24551,"run_id":22260,"accession_number":"0001213900-26-086123","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This is an investor presentation disclosing Psyence BioMed's clinical development strategy, portfolio progress, and strategic positioning in psychedelic therapeutics. The presentation highlights material operational milestones including Phase IIb trial enrollment in Australia (87 patients dosed with NPX-5 for Adjustment Disorder in cancer palliative care), FDA Pre-IND feedback received, and the company's vertically integrated platform through its strategic equity stake in PsyLabs. While the presentation contains forward-looking statements and market opportunity discussion, the substantive disclosure concerns the company's operational and clinical development pathway, manufacturing partnerships, and regulatory progress—operational matters that would affect a reasonable investor's assessment of the company's execution capability and near-term catalysts.","company_name":"PSYENCE BIOMEDICAL LTD.","ticker":"PBMWW","filing_date":"2026-08-06","form":"6-K","submitted_at":null,"items":[{"id":25147,"accession_number":"0001213900-26-086123","item_number":"EX-99.1","item_title":"ea030057901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This is an investor presentation disclosing Psyence BioMed's clinical development strategy, portfolio progress, and strategic positioning in psychedelic therapeutics. The presentation highlights material operational milestones including Phase IIb trial enrollment in Australia (87 patients dosed with NPX-5 for Adjustment Disorder in cancer palliative care), FDA Pre-IND feedback received, and the company's vertically integrated platform through its strategic equity stake in PsyLabs. While the presentation contains forward-looking statements and market opportunity discussion, the substantive disclosure concerns the company's operational and clinical development pathway, manufacturing partnerships, and regulatory progress—operational matters that would affect a reasonable investor's assessment of the company's execution capability and near-term catalysts.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:10:13.260133+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25147,"accession_number":"0001213900-26-086123","item_number":"EX-99.1","item_title":"ea030057901ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This is an investor presentation disclosing Psyence BioMed's clinical development strategy, portfolio progress, and strategic positioning in psychedelic therapeutics. The presentation highlights material operational milestones including Phase IIb trial enrollment in Australia (87 patients dosed with NPX-5 for Adjustment Disorder in cancer palliative care), FDA Pre-IND feedback received, and the company's vertically integrated platform through its strategic equity stake in PsyLabs. While the presentation contains forward-looking statements and market opportunity discussion, the substantive disclosure concerns the company's operational and clinical development pathway, manufacturing partnerships, and regulatory progress—operational matters that would affect a reasonable investor's assessment of the company's execution capability and near-term catalysts.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:10:13.260133+00:00","company_name":"PSYENCE BIOMEDICAL LTD.","ticker":"PBMWW","filing_date":"2026-08-06"}]}